Pfizer’s Covid-19 vaccine for healthy children under 5 is on the brink of losing FDA authorization—a development that could reshape pediatric vaccination strategies and ripple through the biotech and healthcare investment landscape. At Extreme Investor … Read more
Merck’s New RSV Shot: A Game-Changer for Infant Health and What It Means for Investors The recent unanimous recommendation by the revamped Advisory Committee on Immunization Practices (ACIP) to include Merck’s Enflonsia in the government’s … Read more
The recent shakeup at the Advisory Committee on Immunization Practices (ACIP) marks a pivotal moment in U.S. vaccine policy—one that investors and healthcare advisors cannot afford to overlook. Health and Human Services Secretary Robert F. … Read more
Vaccine Policy Shake-Up: What Investors Need to Know About the New ACIP and Thimerosal Debate A seismic shift is underway in U.S. vaccine advisory circles, with Health and Human Services Secretary Robert F. Kennedy Jr. … Read more